<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760459</url>
  </required_header>
  <id_info>
    <org_study_id>ORT-2558-03245</org_study_id>
    <secondary_id>054/2559</secondary_id>
    <nct_id>NCT02760459</nct_id>
  </id_info>
  <brief_title>Effects of Perioperative Intravenous Dexamethasone on the Severity of Persistent Postsurgical Pain After Total Knee Arthroplasty : A Prospective, Randomized, Double-blind, Placebo-controlled Trial</brief_title>
  <official_title>Effects of Perioperative Intravenous Dexamethasone on the Severity of Persistent Postsurgical Pain After Total Knee Arthroplasty : A Prospective, Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <brief_summary>
    <textblock>
      To compare the effects of perioperative intravenous Dexamethasone with a placebo on the
      severity of persistent postsurgical pain after total knee arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is not clear whether perioperative intravenous Dexamethasone has an effect on severity of
      persistent postsurgical pain (PPSP) after total knee arthroplasty (TKA). The research
      hypothesis is that TKA patients experience less severe PPSP after administration of
      perioperative intravenous Dexamethasone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified WOMAC scores for pain at 12 weeks postoperative</measure>
    <time_frame>12 weeks</time_frame>
    <description>using the modified Thai version of the Western Ontario and McMaster (WOMAC) osteoarthritis index for knee osteoarthritis questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for pain during a five-meter walk (0-100)</measure>
    <time_frame>postoperatively at 24, 30, 48, 54, 72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for pain during 45 degree active knee flexion (0-100)</measure>
    <time_frame>postoperatively at 6, 24, 30, 48, 54, 72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for current pain at rest in a supine position (0-100)</measure>
    <time_frame>postoperatively at 6, 24, 30, 48, 54, 72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales for maximum pain at rest over the last 24 hours and minimum pain at rest over the last 24 hours (0-100)</measure>
    <time_frame>postoperatively at 0-24, 24-48, 48-72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale values for nausea (0-100)</measure>
    <time_frame>postoperatively at 6, 24, 30, 48, 54, 72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption (mg.)</measure>
    <time_frame>during the first 0-24, 24-48, and 48-72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-emetic medicine consumption (mg.)</measure>
    <time_frame>during the first 0-24, 24-48, and 48-72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum degree of active knee flexion</measure>
    <time_frame>postoperatively at 24, 48, 72 hrs, 2 weeks, 6 weeks, and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified WOMAC scores for pain</measure>
    <time_frame>postoperatively at weeks 2 and 6</time_frame>
    <description>using the modified Thai version of the Western Ontario and McMaster (WOMAC) osteoarthritis index for knee osteoarthritis questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>evaluated postoperatively at weeks 2, 6 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of Dexamethasone 10 mg IV postoperatively at 24 and 48 hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive sterile normal saline solution, serving as placebo, IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of placebo IV postoperatively 24 and 48 hrs. Both Dexamethasone and normal saline solution will be administered as an IV push.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline solution</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 40 years (45)

          -  Primary knee osteoarthritis diagnosed using the American College of Rheumatology
             criteria (46)

          -  Undergoing elective, primary and unilateral total knee arthroplasty

          -  American Society of Anesthesiology (ASA) physical status class 1-3

          -  BMI &lt; 40 kg/m2

        Exclusion Criteria:

          -  History of active rheumatic diseases

          -  History of previous musculoskeletal injury of the same knee for excluding patients
             with secondary knee osteoarthritis

          -  History of previous surgery on the same knee

          -  History of adverse effects from medications to be used in this study

          -  Contraindication to spinal anesthesia

          -  History of psychiatric disorders or cognitive impairment

          -  Contraindication to corticosteroid agents

          -  Poorly controlled diabetes mellitus (HbA1C &gt; 7.5)

          -  Poorly controlled hypertension

          -  History of ischemic heart disease or peripheral arterial disease or cerebrovascular
             disease

          -  Hepatic insufficiency (Child-Pugh score &gt; 5)

          -  Renal insufficiency (Creatinine clearance &lt; 30 mL/min)

          -  History of cataracts or glaucoma or ocular hypertension

          -  History of steroid or immunosuppressive drug use within 6 months of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nitchanant Kitcharanant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Orthopedics, Faculty of Medicine, Chiang Mai University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nitchanant Kitcharanant, MD</last_name>
    <phone>+66871071133</phone>
    <email>nk_win@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Orthopedics, Chiang Mai University</name>
      <address>
        <city>ChiangMai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitchanant Kitchatanant</last_name>
      <phone>+66871071133</phone>
      <email>nk_win@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>1. Callahan CM, Drake BG, Heck DA, Dittus RS. Patient outcomes following tricompartmental total knee replacement. A meta-analysis. JAMA. 1994;271(17):1349-57. 2. Grosu I, Lavand'homme P, Thienpont E. Pain after knee arthroplasty: an unresolved issue. Knee Surg Sports Traumatol Arthrosc. 2014;22(8):1744-58.</citation>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiang Mai University</investigator_affiliation>
    <investigator_full_name>Nitchanant Kitcharanant</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

